| Previous Close | 24.75 |
| Open | 24.64 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1100 |
| Day's Range | 24.60 - 24.75 |
| 52 Week Range | 21.17 - 25.50 |
| Volume | 2 |
| Avg. Volume | 2,604 |
| Net Assets | 24.47M |
| NAV | 24.47 |
| PE Ratio (TTM) | N/A |
| Yield | 0.08% |
| YTD Return | 3.25% |
| Beta (3Y Monthly) | 6.34 |
| Expense Ratio (net) | 0.78% |
| Inception Date | 2006-09-18 |
Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the.
Montrouge, France, October 30, 2018 DBV Technologies Reports September 30, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in Part B of the EPITOPE (EPIT in TOddlers with PEanut Allergy) trial. EPITOPE is a two-part, pivotal Phase III clinical trial assessing the safety and efficacy of Viaskin Peanut 250 µg for the treatment of peanut-allergic toddlers one to three years of age.
DBV Technologies (Euronext: DB - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. Viaskin Peanut is the Company's lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin.
Montrouge, France, September 25, 2018 DBV Technologies to Present at the Cantor Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 -.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its planned safety review of Part A of the EPITOPE (EPIT in TOddlers with PEanut Allergy) trial of Viaskin Peanut in peanut-allergic toddlers ages one to three. The DSMB did not identify any safety concerns for patients enrolled in Part A of the trial, recommending that the study continue as planned with the 250 µg dose selected for investigation in Part B. Following this positive DSMB recommendation, the Company plans to initiate Part B of the EPITOPE study in the fourth quarter of 2018 to assess the efficacy and safety of Viaskin Peanut 250 µg for 12 months.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2018 financial results. The interim financial report is available on the Investor Relations section of the Company's website, https://www.dbv-technologies.com/investor-relations/. First half 2018 financial statements were subject to a limited review by the Company's external auditors.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), the Geneva University Hospitals (HUG) and BioNet-Asia Co. Ltd presented new data from a Phase I study evaluating the safety and immunogenicity of boosting young adults against pertussis toxin (PT) with an investigational epicutaneous patch containing recombinant PT (Viaskin-PT). The new results, which were presented at the 5th European Congress of Immunology (ECI) in Amsterdam, Netherlands, September 2-5, 2018, by Dr. Olga Chatzis and Prof. Claire-Anne Siegrist from HUG, highlighted data from two additional cohorts showing that following skin preparation with an epidermal laser, anti-PT booster responses elicited by Viaskin-PT were comparable to those elicited by Boostrix® dTpa, an injectable approved booster vaccine.
DBV Technologies to Attend Upcoming Investor Conferences. DBV Technologies, a clinical-stage biopharmaceutical company, today announced that members of its management team will present and host investor ...